A phase III study to evaluate the safety and efficacy of house dust mite sublingual immunotherapy (Actair) in children with allergic rhinitis

Trial Profile

A phase III study to evaluate the safety and efficacy of house dust mite sublingual immunotherapy (Actair) in children with allergic rhinitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2017 According to a Stallergenes Greer plc media release, a New Drug Application (NDA) for ACTAIR, an investigational allergy immunotherapy sublingual tablet, for the treatment of house dust mite (HDM) induced allergic rhinitis in children 5 to 11 years old has been submitted in Japan. The submission is based on data from this trial.
    • 27 Jan 2017 Based on the result of this study Shionogi is working towards getting the indication for five-to-eleven-year-old patients with allergic rhinitis caused by house dust mite, according to a company media release.
    • 27 Jan 2017 Primary endpoint has been met. (Average adjusted symptoms score), as reported in a Shionogi Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top